At the news
? NEUTRALIMPACT 3/10 6-K filed Sep 2, 2026 at 07:33 ET
Purple Biotech announced a USPTO Notice of Allowance for a patent covering tri-specific antibody constructs and methods of use, strengthening IP protection for its CAPTN-3 modular platform. This is a routine IP milestone for a clinical-stage company with a $3M market cap and no revenue, providing no near-term financial catalyst.
- USPTO issued Notice of Allowance for patent application covering tri-specific antibody constructs and methods of use.
- Patent strengthens IP protection for CAPTN-3 modular platform for conditionally activated multispecific antibodies.
- Lead candidate IM1240 is advancing toward the clinic; second candidate IM1305 is in preclinical development.
- Company market cap is approximately $3M with no reported revenue from the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access